The development of new vaccines is challenging and requires profound knowledge of processes and high-quality equipment. New bioprocess technologies such as single-use equipment and process automation open up novel possibilities for quality control and validation. This is especially important in GMP regulated environments such as in the development and manufacturing of new vaccines.
The COVID-19 pandemic starting in 2020 underlined the strong need for the efficient development of new processes. The fast and reliable tech transfer of these processes to scale up to clinical production volumes is key for the efficient development of new vaccinations.